MILabs enhances its preclinical micro-CT systems for Coronavirus research

MILabs enhances its preclinical micro-CT systems for Coronavirus research

Based on recent on-line reports starting to appear and published in Radiology, diagnostic X-ray CT is able to detect COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2), in individuals with high clinical suspicion of the virus — even in cases with negative initial DNA tests. Therefore, to facilitate coronavirus vaccine and therapy research, MILabs has enhanced its preclinical line of micro-CT systems with unique capabilities for in-vivo chest imaging of laboratory animals, from mice to ferrets.

These include gated virtual bronchoscopy, dual-gated cardiac and respiratory acquisitions as well as sensor-free respiratory-gated imaging of multiple animals simultaneously. Now you can obtain high-quality detailed imagines from your own disease models, or from commercially available models such as the K18-hACE2 transgenic mouse model .

Ultra-high resolution in-vivo lung imaging and virtual bronchoscopy

The unique ability of MILabs U-CT of imaging at ultra-high-resolution animals from small mouse to guinea pigs and ferrets, provides a noninvasive method that allows studying the smallest bronchi, precisely determining the location of pathological processes, and the fastness of response to treatment.

Sensor-free respiratory-gated imaging of up to four mice simultaneously

MILabs U-CT systems enable sensor-free gated imaging of up to four mice simultaneously. This enables high-throughput analysis for genotyping or drug candidate screening. In addition, molecular biomarkers can be employed since the U-CT can be upgraded to molecular CT using PET, SPECT and/or Optical imaging.

MILabs new product catalog illustrates the power of multimodal synergy imaging

MILabs just released its new multimodality preclinical imaging brochure, featuring X-ray CT as well as PET, SPECT and 2D/3D Optical imaging platform. This unique platform offers all four modalities individually or in any combination. No matter what combination; the platform is extremely user friendly.

With testimonials from actual users, this 28-page document underscores its exclusive in-vivo imaging capabilities including:

Best scientifically proven image quality (WMIC Innovation of the Year) with highest in vivo image resolution for all its modalities: PET, SPECT, Optical & CT.
Exclusive multimodal synergy by integrating any modality combination on a single platform
Concurrent multi-isotope PET/SPECT and concurrent multi-isotope PET/PET
Positron-free sub-mm resolution PET for example ¹²⁴I, ⁸²Rb and ⁸⁹Zr
Theranostic imaging of radiotherapy isotopes
CT-guided Quantitative Optical Tomography

How are Molecular Imaging Labs reacting to COVID-19?

As institutions around the world continue to develop their response to the COVID-19 outbreak, most Molecular Imaging Labs are finding themselves in uncharted territory. Join the panel discussion and hear from Dr. Lewis (Memorial Sloan Kettering), Dr. Jacobson (Stanford University), and Dr. Kiessling (RWTH Aachen University) as they discuss how their labs are addressing the impact of COVID-19 and the temporary workplace environments.

Wednesday, Mar 18, 2020
10:00 AM – 11:00 AM EDT / 15:00 – 16:00 CET